Diagnostic and therapeutic challenges in cutaneous and mucosal melanoma: a literature review.
Biuletyn Głównej Biblioteki Lekarskiej · 01.06.2026 · 59 (386) · 157-176
DOI: 10.2478/bgbl-2026-0010 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biuletyn Głównej Biblioteki Lekarskiej, online erschienen am 30.06.2026. Verfasst von Jakub Dudek und 5 weiteren Autor:innen. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Current scientific research demonstrates that cutaneous melanoma and mucosal melanoma are two distinct disease entities, considering the complexities of their diagnosis and treatment. Mucosal melanoma is characterized by a significantly poorer prognosis than cutaneous melanoma, with a 5-year overall survival (OS) rate of less than 20%. Surgical resection remains the gold standard of management; however, there is currently a paradigm shift away from routine, complication-prone completion lymph node dissection toward selective surveillance using serial ultrasound. This approach significantly improves patients’ quality of life without negatively impacting OS. Due to anatomical constraints (e.g., oral cavity, paranasal sinuses), narrow resection margins are supplemented with radiotherapy. Although this effectively reduces the risk of local recurrence, it does not prolong OS due to rapid distant metastasis, which occurs in approximately half of the patients within the first year. In systemic treatment, the standard of care involves dual immune checkpoint blockade (nivolumab plus ipilimumab) as well as BRAF/MEK and tyrosine kinase inhibitors (imatinib, nilotinib). The efficacy of immunotherapy in mucosal melanoma is significantly lower compared to that in cutaneous melanoma. The application of nivolumab plus ipilimumab yields slightly better outcomes than anti-PD-1 monotherapy; however, the proportion of patients achieving a durable response to treatment and the long-term survival rates remain highly unsatisfactory. The insufficient efficacy of current treatment paradigms highlights a critical need for the development of novel strategies. These include the broader application of Mohs micrographic surgery and the implementation of experimental therapies currently under investigation, such as anti-angiogenic treatments, oncolytic viruses, vaccines, adoptive T-cell therapies (e.g. CAR-T), bispecific antibodies (e.g. brenetafusp), and gut microbiome modulation.
Zitieren
APA
Dudek, J., Górecka, W., Dudek, A., Gaweł, B., Sochań, G., & Górecki, M. (2026). Diagnostic and therapeutic challenges in cutaneous and mucosal melanoma: a literature review. Biuletyn Głównej Biblioteki Lekarskiej, 59(386), 157-176. https://doi.org/10.2478/bgbl-2026-0010
Vancouver
Dudek J, Górecka W, Dudek A, Gaweł B, Sochań G, Górecki M. Diagnostic and therapeutic challenges in cutaneous and mucosal melanoma: a literature review. Biuletyn Głównej Biblioteki Lekarskiej. 2026;59(386):157-176. doi:10.2478/bgbl-2026-0010
BibTeX
@article{Dudek2026,
author = {Dudek, Jakub and Górecka, Wiktoria and Dudek, Aleksandra and Gaweł, Bartosz and Sochań, Grzegorz and Górecki, Michał},
title = {Diagnostic and therapeutic challenges in cutaneous and mucosal melanoma: a literature review},
journal = {Biuletyn Głównej Biblioteki Lekarskiej},
year = {2026},
volume = {59},
number = {386},
pages = {157--176},
doi = {10.2478/bgbl-2026-0010}
}
EUVIMED